Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has announced that the Company’s Chairman, Cathal Friel, will be attending the HC Wainwright Global Investment Conference, which is taking place from 12-14 September at the Lotte New York Palace Hotel in New York City, NY, USA.
Poolbeg Pharma to attend HC Wainwright Global Investment Conference
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
Latest Company News
Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs.
Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs.
Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy.
Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy.
Cytokine Release Syndrome (CRS) complicates cancer immunotherapy, but Poolbeg Pharma’s POLB 001 offers a groundbreaking oral solution to enhance patient outcomes.
